Home › Research › Biomarkers
Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment
Kivisäkk P, Magdamo C, Trombetta BA, Noori A, Kuo YKE, Chibnik LB, Carlyle BC, Serrano-Pozo A et al.. Brain communications, 2022-06-14
Topic: Risk, prevention and care in population studies
Plain-language summary
Although recent studies have demonstrated the prognostic utility of plasma biomarkers of Alzheimer pathology or neurodegeneration, such as pTau-181 and NF-L, whether other plasma biomarkers can further improve prediction of cognitive decline is undetermined. We developed a machine learning model to distinguish progressors from stable and used 44 proteins with significantly different plasma levels in progressors versus stable along with age, sex, education and baseline cognition as candidate features. The Olink proteins selected by the model included those associated with vascular injury and neuroinflammation (e.g. The proteins NF-L and PTP-1B were significantly higher in both Alzheimer and non-Alzheimer dementias compared with cognitively normal individuals. In summary, our findings suggest that plasma biomarkers of inflammation and vascular injury are associated with cognitive decline. Developing a plasma biomarker profile could aid in prognostic deliberations and identify individuals at higher risk of dementia in clinical practice.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 60 participants. A machine learning model using plasma proteins linked to inflammation and vascular injury, along with age, sex, education and baseline cognition, was developed to distinguish people with mild cognitive impairment who progressed from those who stayed stable. Reported effect size: 86.7%; 78.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kivisäkk, P., Magdamo, C., Trombetta, B. A., Noori, A., Kuo, Y. K. E., Chibnik, L. B., et al. (2022). Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain communications. https://doi.org/10.1093/braincomms/fcac155
Vancouver
Kivisäkk P, Magdamo C, Trombetta BA, Noori A, Kuo YKE, Chibnik LB, et al. Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain communications. 2022. doi:10.1093/braincomms/fcac155. PMID: 35800899.
BibTeX
@article{kivisakk2022-35800899,
author = {Kivisäkk, P. and Magdamo, C. and Trombetta, B. A. and Noori, A. and Kuo, Y. K. E. and Chibnik, L. B. and Carlyle, B. C. and Serrano-Pozo, A. and others},
title = {{Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment}},
journal = {Brain communications},
year = {2022},
doi = {10.1093/braincomms/fcac155},
pmid = {35800899},
url = {https://doi.org/10.1093/braincomms/fcac155}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Although recent studies have demonstrated the prognostic utility of plasma biomarkers of Alzheimer pathology or neurodegeneration, such as pTau-181 and NF-L, whether other plasma biomarkers can further improve prediction of cognitive decline is undetermined.
- We developed a machine learning model to distinguish progressors from stable and used 44 proteins with significantly different plasma levels in progressors versus stable along with age, sex, education and baseline cognition as candidate features.
- The Olink proteins selected by the model included those associated with vascular injury and neuroinflammation (e.g.
- The proteins NF-L and PTP-1B were significantly higher in both Alzheimer and non-Alzheimer dementias compared with cognitively normal individuals.
- In summary, our findings suggest that plasma biomarkers of inflammation and vascular injury are associated with cognitive decline.
Why it matters
A machine learning model using plasma proteins linked to inflammation and vascular injury, along with age, sex, education and baseline cognition, was developed to distinguish people with mild cognitive impairment who progressed from those who stayed stable. This suggests a plasma profile could help predict cognitive decline, but it is a prognostic tool and not a treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants60
- Effect size86.7%; 78.6%
- Evidence strengthModerate
How this study scored 62/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain communications) |
| Journal's citation record | 0 / 4 | Brain Communications: journal h-index 67 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 60 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 43 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 5.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Steven Edward Arnold: h-index 125 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35800899) |
| Free to read | 2 / 2 | Free to read |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.